Obermatt
See Similar Stocks →

Shinpoong Pharmaceutical

KSC:019170 · KR7019170000
PharmaceuticalsSmall

360

68
Medium confidence — indicative
Profit price10
Owner Earnings Yield72
Dividend Yield1
Price/Sales19
EV / Gross Profit37
Price/Book28
Return on Capital65
Cash Return on Capital73
Return on Equity65
EBIT Margin63
Gross Profitability74
Cash Conversion77
Accruals46
Owner Earnings Margin77
Sales growth21
Profit growth71
Reinvestment12
Price momentum45
Debt load75
Refinancing39
Debt Payback100
Liquidity56
Analyst ratings—
Expectations trend—
Market mood53
Value Creation12/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Shinpoong Pharmaceutical clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
TypePublic Company
ExchangeKOSE
Employees32
Websiteshinpoong.co.kr
ISINKR7019170000
Last UpdateApr 2, 2026
Indices
KOSPI (South Korea)
Themes
Pain ManagementInfectious DiseasesInflammationOncologyBiotechnologyMedical

Description

Analysis

Quality compounder

Shinpoong Pharmaceutical Co.,Ltd is a quality compounder: a well-run business trading at a price that reflects what it is worth.

The price is fair. You pay 23.2× its owner earnings: the cash an owner could take out each year, which is in the historically fair zone.

The trajectory is mixed and the balance sheet is sturdy. The company scores 12/20 on our value-creation score: creating some value.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
6
20232026

All-time high

15

Mar 2026

All-time low

3

Jan 2023

Average rank

8

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
19
—
—
14
Price/Earnings
6
—
—
—
Price/Book
28
—
—
16
Dividend Yield
1
—
—
1
Value (overall)
6
—
—
15

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Shinpoong Pharmaceutical with its peers
Dongwha Pharm
KSC:000020
44
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Kukje Pharma
KSC:002720
43
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Hana Pharm
KSC:293480
88
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Jeil Pharmaceutical
KSC:271980
70
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Whanin Pharm
KSC:016580
99
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Yungjin Pharm
KSC:003520
34
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →